INIGO DE MIGUEL BERIAIN

Dr. INIGO DE MIGUEL BERIAIN


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
IBINIGO DE MIGUEL BERIAIN
INIGO DE MIGUEL BERIAIN

1 October 2024 in The CRISPR Journal
Verified
Journal Article
Open access
JRJon Rueda
Jon Rueda
IBINIGO DE MIGUEL BERIAIN
INIGO DE MIGUEL BERIAIN
LMLluis Montoliu
Lluis Montoliu
Casgevy, the world’s first approved CRISPR-based cell therapy, has been priced at $2.2 million per patient. Although this hefty price tag was widely anticipated, the extremely high cost of this and other cell and gene therapies poses a major ethical issue in terms of equitable access and global health. In this Perspective, we argue that lowering the prices of future CRISPR therapies is an urgent ethical imperative. Although we focus on Casgevy as a case study, much of our analysis can be extrapolated to the controversies over affordable access to other gene and cell therapies. First, we explain why this first-of-its-kind CRISPR therapy might be so expensive. We then analyze the ethical issues of equity and global health of early CRISPR treatments. Next, we discuss potential solutions to lower the prices of CRISPR gene therapies. We conclude that the approval of CRISPR transforms our obligations of justice and compels us to bring future gene therapies to the maximum possible number of patients with serious genetic diseases at affordable prices.

19 February 2018 in Law, Probability and Risk
Verified
Journal Article
Closed access
PDF file
IBINIGO DE MIGUEL BERIAIN
INIGO DE MIGUEL BERIAIN
On 13 July 2016, the Supreme Court of Wisconsin published a crucial decision which ruled for the first time ever about the constitutionality of using algorithms in sentencing. The ruling accepted their use, arguing that defendants’ right to due process was not violated by the mere fact that they could not gain access to an adequate explanation of the algorithm. To support this position, the Court stated that the accuracy of the tools and the capacity of the judges to understand their possible malfunctioning were enough to ensure the defendants’ rights. This article criticizes this ruling by unveiling the contradictions and misunderstandings involved in the rationale embedded in the sentence. As a consequence, it advocates the use of open source algorithms in our justice systems or, at least, in sentencing.

2 July 2020 in Information, Communication & Society
Verified
Journal Article
Closed access
IBINIGO DE MIGUEL BERIAIN
INIGO DE MIGUEL BERIAIN
Begoña SanzBegoña Sanz
Begoña Sanz
GLGuillermo Lazcoz
Guillermo Lazcoz
Diagnosis and clinical decision-making based on Machine Learning technologies are showing significant advances that may change the functioning of our health care systems. They promise more effective and efficient healthcare at a lower cost. Even though evidence suggests that all these promises have yet to be demonstrated in clinical practice, it is undeniable that these technologies are already re-signifying the relationships on the health care landscape, particularly in the physician-patient relationship, which we can already redefine as a ‘physician-computer-patient relationship’. This new scenario is undoubtedly promising, but it also poses some fundamental issues that need an urgent answer. An inappropriate use of Machine Learning might involve a dramatic loss in the patients’ rights to informed consent or possible discrimination reflecting their personal circumstances. Unfortunately, the traditional principles incorporated by medical law are insufficient to face this challenge. Our most recent regulatory framework, defined by the General Regulation on Data Protection, might be useful in order to avoid this scenario since it includes the right not to be subject to a decision based solely on automated processing. In this paper, however, we argue that this legal tool is adequate but not sufficient to address the legal, ethical and social challenges that Machine Learning technologies pose to patients’ rights and health care givers’ capacities. Therefore, further development of the regulation on this topic and the development of new actors such as the Health Information Counsellors, will be necessary.

4 March 2022 in BMC Medical Ethics
Verified
Journal Article
Open access
PDF file
TITetsuya Ishii
Tetsuya Ishii
IBINIGO DE MIGUEL BERIAIN
INIGO DE MIGUEL BERIAIN
Background: Some persons conceived with donor gametes react negatively when they found their birth via donor conception. They request access to information about and seek to communicate with the donor. However, some countries mandate donor anonymity. Other countries allow donor-conceived persons to access donor information, but they can only use this access if their parents have disclosed donor conception to them. We investigated a thorny issue of donor conception: whether donor conception should be shifted from an anonymous basis to a non-anonymous basis. Methods: We review the issues and concerns regarding donor conception. We then consider the impact of direct-to-consumer genetic testing on donor conception, as well as the influence of donor conception on offspring’s identity and the potential of different types of donors. To discuss the future policy of donor conception, the policies on the anonymity of gamete donors were investigated using publicly-available documents in 15 countries. Results: The aim of mandating donor anonymity is to protect the privacy of the donor and intended parents. However, the diffusion of direct-to-consumer genetic testing may make it impossible to maintain anonymity. Birth via donor conception shapes the offspring’s identity, and the donor may further influence the development of offspring’s identity through communications. It remains important to disclose donor conception to donor-conceived offspring and to provide them with donor information. However, that information might be insufficient for some donor-conceived persons. Here are benefits to having open-identity donors and known donors. Such donors can make an agreement with the parents regarding future communication with the offspring, although both sides should respect privacy. Subsequent counseling for all parties involved can result in better tripartite communication agreements. Conclusions: In sum, ethical and practical issues that complicate donor anonymity are driving a shift to non-anonymous donor conception, in which all parties come to a communication agreement. To pave the way for such a donor conception system, transitional measures can be put into place. For countries that already adopted non-anonymous donor conception, ensuring the communication agreements is important to protect the rights of parents, donor, and offspring.

1 January 2020 in Journal of Law and the Biosciences
Verified
Journal Article
Open access
PDF file
IBINIGO DE MIGUEL BERIAIN
INIGO DE MIGUEL BERIAIN
MMMarina Morla-González
Marina Morla-González
Recently, the US Food and Drug Administration has given a landmark approval to the very first digital pill with a sensor embedded in the inside. These are complex systems that include a drug and an electronic tracker that is activated when the patient takes the pill. Accordingly, they might be an excellent tool for monitoring and potentially improving patients’ adherence to prescriptions. This would serve well to avoid unnecessary healthcare costs and reduce the anxiety of patients and their relatives. However, digital pills might also diminish patient autonomy, reduce privacy, or promote inadequate use of pharmaceutical resources. This article is aimed at contributing to adequate use of this new tool by showing the main ethical and social issues they involve and proposing measures meant to address them. Finally, we conclude by defending the idea that these new systems should be seen as means of complementing traditional strategies to promote adherence to treatment, and not as substitutes.